Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:93
  • preuzimanja u poslednjih 30 dana:35

Sadržaj

članak: 1 od 53  
Back povratak na rezultate
2020, vol. 39, br. 4, str. 500-507
C-reaktivni protein kao rani indikator ozbiljnosti infekcije virusom COVID-19
aMohammed VI University of Health Sciences (UM6SS), Cheikh Khalifa International University Hospital, Department of Hematology, Casablanca, Morocco
bMohammed VI University of Health Sciences (UM6SS), International School of Public Health, Laboratory of Medical Evaluation and Health Economics, Casablanca, Morocco
cMohammed VI University of Health Sciences (UM6SS), National Reference Laboratory, Casablanca, Morocco
dMohammed VI University of Health Sciences (UM6SS), Cheikh Khalifa International University Hospital, Department of Anesthesiology and Reanimation, Casablanca, Morocco

e-adresamahnach@um6ss.ma, szbiri@um6ss.ma
Ključne reči: COVID-2019; SARS-CoV-2; C-reaktivni protein; rani pokazatelj; ozbiljnost
Sažetak
Uvod: Podaci za predviđanje težine stanja pacijenata sa infekcijom COVID-19 su retki i još uvek se istražuju. Retrospektivno smo istražili da li nivo C-reaktivnog proteina (CRP) može da posluži kao rani indikator ozbiljnosti bolesti pri infekciji virusom COVID-19 u poređenju sa drugim hematološkim i upalnim markerima. Metode: Uključili smo sve pacijente koji su uzastopno primljeni u Međunarodnu univerzitetsku bolnicu Šeik Kalifa u Kazablanki, Maroko, u periodu od februara do aprila 2020. godine, sa dijagnozom COVID-19 infekcije potvrđenom pomoću virusne nukleinske kiseline COVID-19 putem RT-PCR. Kompletna krvna slika i nivo seruma CRP rutinski su mereni na prijemu. Svi klinički i laboratorijski podaci pacijenata su prikupljeni i analizirani. Klasifikacija težine bolesti bila je u skladu sa kliničkom klasifikacijom privremenih uputstava SZO, a lečenje pacijenata prilagođeno međunarodnim smernicama. Izvršili smo procenu ROC krive parametara analize krvi kao i njihovu povezanost sa težinom bolesti COVID-19. Rezultati: U istraživanje je uključeno 145 pacijenata sa infekcijom COVID-19. Srednja vrednost starosti bila je 50 godina (32-63 godine), a 75 pacijenata (51,7%) bili su muškarci. U lakšu grupu svrstan je 101 pacijent, a u težu 44. Na osnovu težine bolesti primećene su značajne razlike u starosti, polu, komorbiditetima i respiratornim simptomima. Slično tome, biološka analiza otkrila je značajne razlike u broju neutrofila, broju limfocita, broju eozinofila i nivou CRP-a. Međutim, prema ROC krivama ovih laboratorijskih biomarkera, AUC (oblast ispod krive) CRP-a na 0,872 bio je značajno veći od svih ostalih parametara. Dalje, CRP je nezavisno povezan sa težinom bolesti COVID-19 (OR = 1,11, 95% IC (1,01-1,22) i or = 1,13, 95% IC (1,04-1,23)). Zaključak: Ovo istraživanje je otkrilo da nivo CRP-a pri prijemu predstavlja jednostavan i nezavisan faktor koji može biti koristan za rano otkrivanje težine bolesti COVID-19 i lako sprovođenje primarne nege.
Reference
Ballou, S.P., Kushner, I. (1992) C-reactive protein and the acute phase response. Adv Intern Med, 37: 313-36
Chalmers, S., Khawaja, A., Wieruszewski, P.M., Gajic, O., Odeyemi, Y. (2019) Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: The role of inflammatory biomarkers. World J Crit Care Med, 8(5): 59-71
Chen, W., Zheng, K.I., Liu, S., Yan, Z., Xu, C., Qiao, Z. (2020) Plasma CRP level is positively associated with the severity of COVID-19. Annals of Clinical Microbiology and Antimicrobials, 19(1): 18-18
Coster, D., Wasserman, A., Fisher, E., Rogowski, O., Zeltser, D., Shapira, I., Bernstein, D., Meilik, A., Raykhshtat, E., Halpern, P., Berliner, S., Shenhar-Tsarfaty, S., Shamir, R. (2020) Using the kinetics of C-reactive protein response to improve the differential diagnosis between acute bacterial and viral infections. Infection, 48(2): 241-248
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395(10223): 497-506
Li, L., Huang, T., Wang, Y., Wang, Z.Q., Liang, Y., Huang, T., Zhang, H., Sun, W., Wang, Y.Q. (2020) COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. Journal of Medical Virology, 92(6): 577-583
Lippi, G., Plebani, M. (2020) Laboratory abnormalities in patients with COVID-2019 infection. Clinical Chemistry and Laboratory Medicine (CCLM), 58(7): 1131-1134
Liu, F., Li, L., Xu, M., Wu, J., Luo, D., Zhu, Y., Li, B., Song, X., Zhou, X. (2020) Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. Journal of Clinical Virology, 127: 104370-104370
Luo, X., Zhou, W., Yan, X., Guo, T., Wang, B., Xia, H., Ye, L., Xiong, J., Jiang, Z., Liu, Y., Zhang, B., Yang, W. (2020) Prognostic value of C-reactive protein in patients with coronavirus 2019. Clinical Infectious Diseases
Marnell, L., Mold, C., Du, C.T.W. (2005) C-reactive protein: Ligands, receptors and role in inflammation. Clinical Immunology, 117(2): 104-111
Ministry of Health of Morocco (2020) Coronavirus disease COVID-19. http://www.covidmaroc.ma/Pages/ProfessionnelSanteAR.aspx
Mortensen, R.F. (2001) C-reactive protein, inflammation, and innate immunity. Immunologic Research, 24(2): 163-176
Nehring, S.M., Goyal, A., Bansal, P., Patel, B.C. (2020) C-Reactive Protein (CRP). Treasure Island, FL: StatPearls Publishing
Peng, F., Tu, L., Yang, Y., Hu, P., Wang, R., Hu, Q., Cao, F., Jiang, T., Sun, J., Xu, G., Chang, C. (2020) Management and treatment of COVID-19: The Chinese experience. Canadian Journal of Cardiology, 36(6): 915-930
Phelan, A.L., Katz, R., Gostin, L.O. (2020) The novel coronavirus originating in Wuhan China: Challenges for global health governance. JAMA, 323 (8): 709-10
Ponti, G., Maccaferri, M., Ruini, C., Tomasi, A., Ozben, T. (2020) Biomarkers associated with COVID-19 disease progression. Critical Reviews in Clinical Laboratory Sciences, 57(6): 389-399
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., Tian, D. (2020) Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases, 71(15): 762-768
Tan, C., Huang, Y., Shi, F., Tan, K., Ma, Q., Chen, Y., Jiang, X., Li, X. (2020) C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. Journal of Medical Virology, 92(7): 856-862
Tan, L., Kang, X., Ji, X., Li, G., Wang, Q., Li, Y., Wang, Q., Miao, H. (2020) Validation of predictors of disease severity and outcomes in COVID-19 patients: A descriptive and retrospective study. Med
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., Peng, Z. (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 323(11): 1061-1069
Wang, G., Wu, C., Zhang, Q., Wu, F., Yu, B., Lv, J., Li, Y., Li, T., Zhang, S., Wu, C., Wu, G., Zhong, Y. (2020) C-reactive protein level may predict the risk of COVID-19 aggravation. Open Forum Infectious Diseases, 7(5)
Wang, L. (2020) C-reactive protein levels in the early stage of COVID-19. Médecine et Maladies Infectieuses, 50(4): 332-334
Warusevitane, A., Karunatilake, D., Sim, J., Smith, C., Roffe, C. (2016) Early diagnosis of pneumonia in severe stroke: Clinical features and the diagnostic role of C-reactive protein. PLoS One, 11(3): e0150269-e0150269
World Health Organization (2020) Laboratory testing for 2019 novel coronavirus (2019nCoV) in suspected human cases. January 17; https://www.who.int/publications-detail/laboratory-testing-for-2019-novelcoronavirus-in-suspected-human-cases
World Health Organization (2020) Coronavirus disease 2019 (COVID-19): Situation report-128. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200527-covid-19-sitrep-128.pdf?sfvrsn=11720c0a_2
World Health Organization (2020) Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance. 13 March, https://apps.who.int/iris/handle/10665/331446
Yuki, K., Fujiogi, M., Koutsogiannaki, S. (2020) COVID-19 pathophysiology: A review. Clinical Immunology, 215: 108427-108427
Zhang, J., Yu, M., Tong, S., Liu, L., Tang, Liang-V. (2020) Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China. Journal of Clinical Virology, 127: 104392-104392
Zhao, Q., Meng, M., Kumar, R., Wu, Y., Huang, J., Deng, Y., Weng, Z., Yang, L. (2020) Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. International Journal of Infectious Diseases, 96: 131-135
Zhou, Y., Fu, B., Zheng, X., Wang, D., Zhao, C., Qi, Y., Sun, R., Tian, Z., Xu, X., Wei, H. (2020) Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. Cold Spring Harbor Laboratory, BioRxiv
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G.F., Tan, W. (2020) A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine, 382(8): 727-733
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
PMC ID: PMC7710381
DOI: 10.5937/jomb0-27554
objavljen u SCIndeksu: 02.10.2020.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0